218 related articles for article (PubMed ID: 29263255)
1. Simultaneous Insertion of Two Ligands in gD for Cultivation of Oncolytic Herpes Simplex Viruses in Noncancer Cells and Retargeting to Cancer Receptors.
Leoni V; Petrovic B; Gianni T; Gatta V; Campadelli-Fiume G
J Virol; 2018 Mar; 92(6):. PubMed ID: 29263255
[TBL] [Abstract][Full Text] [Related]
2. Dual Ligand Insertion in gB and gD of Oncolytic Herpes Simplex Viruses for Retargeting to a Producer Vero Cell Line and to Cancer Cells.
Petrovic B; Leoni V; Gatta V; Zaghini A; Vannini A; Campadelli-Fiume G
J Virol; 2018 Mar; 92(6):. PubMed ID: 29263257
[TBL] [Abstract][Full Text] [Related]
3. A Strategy for Cultivation of Retargeted Oncolytic Herpes Simplex Viruses in Non-cancer Cells.
Leoni V; Gatta V; Casiraghi C; Nicosia A; Petrovic B; Campadelli-Fiume G
J Virol; 2017 May; 91(10):. PubMed ID: 28250120
[TBL] [Abstract][Full Text] [Related]
4. Syncytial Mutations Do Not Impair the Specificity of Entry and Spread of a Glycoprotein D Receptor-Retargeted Herpes Simplex Virus.
Okubo Y; Uchida H; Wakata A; Suzuki T; Shibata T; Ikeda H; Yamaguchi M; Cohen JB; Glorioso JC; Tagaya M; Hamada H; Tahara H
J Virol; 2016 Dec; 90(24):11096-11105. PubMed ID: 27707922
[TBL] [Abstract][Full Text] [Related]
5. The Engineering of a Novel Ligand in gH Confers to HSV an Expanded Tropism Independent of gD Activation by Its Receptors.
Gatta V; Petrovic B; Campadelli-Fiume G
PLoS Pathog; 2015 May; 11(5):e1004907. PubMed ID: 25996983
[TBL] [Abstract][Full Text] [Related]
6. HSV as A Platform for the Generation of Retargeted, Armed, and Reporter-Expressing Oncolytic Viruses.
Menotti L; Avitabile E; Gatta V; Malatesta P; Petrovic B; Campadelli-Fiume G
Viruses; 2018 Jun; 10(7):. PubMed ID: 29966356
[TBL] [Abstract][Full Text] [Related]
7. Antibody Screening System Using a Herpes Simplex Virus (HSV)-Based Probe To Identify a Novel Target for Receptor-Retargeted Oncolytic HSVs.
Ikeda H; Uchida H; Okubo Y; Shibata T; Sasaki Y; Suzuki T; Hamada-Uematsu M; Hamasaki R; Okuda K; Yamaguchi M; Kojima M; Tanaka M; Hamada H; Tahara H
J Virol; 2021 Apr; 95(9):. PubMed ID: 33627393
[TBL] [Abstract][Full Text] [Related]
8. Retargeting Strategies for Oncolytic Herpes Simplex Viruses.
Campadelli-Fiume G; Petrovic B; Leoni V; Gianni T; Avitabile E; Casiraghi C; Gatta V
Viruses; 2016 Feb; 8(3):63. PubMed ID: 26927159
[TBL] [Abstract][Full Text] [Related]
9. Construction of a fully retargeted herpes simplex virus 1 recombinant capable of entering cells solely via human epidermal growth factor receptor 2.
Menotti L; Cerretani A; Hengel H; Campadelli-Fiume G
J Virol; 2008 Oct; 82(20):10153-61. PubMed ID: 18684832
[TBL] [Abstract][Full Text] [Related]
10. Insertion of a ligand to HER2 in gB retargets HSV tropism and obviates the need for activation of the other entry glycoproteins.
Petrovic B; Gianni T; Gatta V; Campadelli-Fiume G
PLoS Pathog; 2017 Apr; 13(4):e1006352. PubMed ID: 28423057
[TBL] [Abstract][Full Text] [Related]
11. Rethinking herpes simplex virus: the way to oncolytic agents.
Campadelli-Fiume G; De Giovanni C; Gatta V; Nanni P; Lollini PL; Menotti L
Rev Med Virol; 2011 Jul; 21(4):213-26. PubMed ID: 21626603
[TBL] [Abstract][Full Text] [Related]
12. Development of an oncolytic HSV vector fully retargeted specifically to cellular EpCAM for virus entry and cell-to-cell spread.
Shibata T; Uchida H; Shiroyama T; Okubo Y; Suzuki T; Ikeda H; Yamaguchi M; Miyagawa Y; Fukuhara T; Cohen JB; Glorioso JC; Watabe T; Hamada H; Tahara H
Gene Ther; 2016 Jun; 23(6):479-88. PubMed ID: 26905369
[TBL] [Abstract][Full Text] [Related]
13. Immunotherapeutic Efficacy of Retargeted oHSVs Designed for Propagation in an Ad Hoc Cell Line.
Vannini A; Leoni V; Sanapo M; Gianni T; Giordani G; Gatta V; Barboni C; Zaghini A; Campadelli-Fiume G
Cancers (Basel); 2021 Jan; 13(2):. PubMed ID: 33445744
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of human tumor growth in mice by an oncolytic herpes simplex virus designed to target solely HER-2-positive cells.
Menotti L; Nicoletti G; Gatta V; Croci S; Landuzzi L; De Giovanni C; Nanni P; Lollini PL; Campadelli-Fiume G
Proc Natl Acad Sci U S A; 2009 Jun; 106(22):9039-44. PubMed ID: 19458262
[TBL] [Abstract][Full Text] [Related]
15. A fully-virulent retargeted oncolytic HSV armed with IL-12 elicits local immunity and vaccine therapy towards distant tumors.
Leoni V; Vannini A; Gatta V; Rambaldi J; Sanapo M; Barboni C; Zaghini A; Nanni P; Lollini PL; Casiraghi C; Campadelli-Fiume G
PLoS Pathog; 2018 Aug; 14(8):e1007209. PubMed ID: 30080893
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of HER2 retargeted herpes simplex virus as therapy for high-grade glioma in immunocompetent mice.
Reisoli E; Gambini E; Appolloni I; Gatta V; Barilari M; Menotti L; Malatesta P
Cancer Gene Ther; 2012 Nov; 19(11):788-95. PubMed ID: 22996742
[TBL] [Abstract][Full Text] [Related]
17. A herpes simplex virus recombinant that exhibits a single-chain antibody to HER2/neu enters cells through the mammary tumor receptor, independently of the gD receptors.
Menotti L; Cerretani A; Campadelli-Fiume G
J Virol; 2006 Jun; 80(11):5531-9. PubMed ID: 16699034
[TBL] [Abstract][Full Text] [Related]
18. B Virus (Macacine Herpesvirus 1) Divergence: Variations in Glycoprotein D from Clinical and Laboratory Isolates Diversify Virus Entry Strategies.
Patrusheva I; Perelygina L; Torshin I; LeCher J; Hilliard J
J Virol; 2016 Oct; 90(20):9420-32. PubMed ID: 27512063
[TBL] [Abstract][Full Text] [Related]
19. Systemic delivery of HER2-retargeted oncolytic-HSV by mesenchymal stromal cells protects from lung and brain metastases.
Leoni V; Gatta V; Palladini A; Nicoletti G; Ranieri D; Dall'Ora M; Grosso V; Rossi M; Alviano F; Bonsi L; Nanni P; Lollini PL; Campadelli-Fiume G
Oncotarget; 2015 Oct; 6(33):34774-87. PubMed ID: 26430966
[TBL] [Abstract][Full Text] [Related]
20. The molecular basis of herpesviruses as oncolytic agents.
Menotti L; Campadelli-Fiume G; Nanni P; Lollini PL; De Giovanni C
Curr Pharm Biotechnol; 2012 Jul; 13(9):1795-803. PubMed ID: 21740356
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
